We secure approvals – US FDA and CE marking before the end of 2020
BioSpectrum Asia|March 2020
Incorporated in early 2018, Pune, India based health tech startup In-Med Prognostics has developed an artificial intelligence (AI) based brain health diagnostic and prognostic tool called NeuroShield, which is one-of-its-kind in India. It is a cloud-based clinical decision support tool for neurological disorders. The tool utilizes three dimensional (3D) based magnetic resonance images to their full potential by extracting data and providing volumetric analysis for the brain and its various structures. The analysis of NeuroShield enables actionable, quantitative, objective decision making to the neuro-physicians for differential diagnosis. To gather more information on this innovative product, BioSpectrum spoke to Dr Latha Poonamallee, Cofounder & Chairperson, In-Med Prognostics, Pune in India. Edited Excerpts;
Dr Manbeena Chawla
We secure approvals – US FDA and CE marking before the end of 2020

What are the major features of NeuroShield that make it one of a kind in India?

NeuroShield is the first such product to be using AI in brain volumetry outside of the US and EU and the first in India. It is also the first to use an ethnicity/ geography-based reference range. One of the reasons the other products were not adopted here in India was because the reference data was not relevant but this approach of ethnicity-based reference is a new approach to using data analytics relevant for different populations. Finally, our cost structure makes it affordable and accessible to all. We spent close to 18 months in the actual development of this product and another year was put in for preparation and research. The company was formed in Jan 2018 and the product was launched in Jan 2020.

What is your current reach and how do you plan to further enhance it?

Right now, we have partnered with over 15 hospitals in major and minor cities. Some of these hospitals like Max Neuro are a chain hospital with 14 hospitals and similarly, Aarthi Scans has over 25 centers. To name a few more, we are associated with hospitals and screening centres such as Sahyadri Hospital, Deenanath Mangeshkar Hospital, NM Medical, P.H diagnostic centre and Noble Hospital. To fulfill our social mission, we also plan to expand our presence in Tier 2 and Tier 3 cities. We also plan to expand our global footprint. We are in talks with hospitals in Dubai, Philippines, Indonesia and Australia. We are also in touch with Abu Dhabi government agency about opening an office in their innovation center.

How do you intend to contribute to mental healthcare in India?

この記事は BioSpectrum Asia の March 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。

この記事は BioSpectrum Asia の March 2020 版に掲載されています。

7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。

BIOSPECTRUM ASIAのその他の記事すべて表示
Ushering Fourth Industrial Revolution in Telangana
BioSpectrum Asia

Ushering Fourth Industrial Revolution in Telangana

Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).

time-read
6 分  |
BioSpectrum Asia April 2024
How Indian Biotech Investments are on a Doubling Spree
BioSpectrum Asia

How Indian Biotech Investments are on a Doubling Spree

A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.

time-read
4 分  |
BioSpectrum Asia April 2024
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
BioSpectrum Asia

"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”

South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.

time-read
5 分  |
BioSpectrum Asia April 2024
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
BioSpectrum Asia

"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"

Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.

time-read
4 分  |
BioSpectrum Asia April 2024
Can Test, Treat, Track Beat Malaria?
BioSpectrum Asia

Can Test, Treat, Track Beat Malaria?

Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.

time-read
8 分  |
BioSpectrum Asia April 2024
Engineering CAR T cell sharpshooters
BioSpectrum Asia

Engineering CAR T cell sharpshooters

Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.

time-read
6 分  |
BioSpectrum Asia April 2024
Addressing Challenges in Cell Therapy Manufacturing
BioSpectrum Asia

Addressing Challenges in Cell Therapy Manufacturing

Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.

time-read
2 分  |
BioSpectrum Asia April 2024
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
BioSpectrum Asia

"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"

Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.

time-read
5 分  |
BioSpectrum Asia April 2024
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
BioSpectrum Asia

Addressing Accessibility and Affordability of CELL & GENE THERAPIES

Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.

time-read
10+ 分  |
BioSpectrum Asia April 2024
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024